



S5 Fig. Survival curves of the adult acute myeloid leukemia (AML) patients in the validation datasets (BeatAML) based on literature-based signature 6 (LBS6) risk scores. The overall survival for high-risk and low-risk groups based on a gene signature in the Beat AML cohort. The curves demonstrate a significant disparity in survival outcomes, with the high-risk group exhibiting markedly poorer survival rates. The statistical significance of this difference is confirmed by a log-rank test ($p=0.0013$), and the hazard ratio (HR) was 1.52 (95% confidence interval, 1.17 to 1.96), highlighting the predictive power of the gene signature on patient prognosis.